Cargando…

The Impact of Renal Impairment on Long-Term Safety and Effectiveness of Drug-Eluting Stents

BACKGROUND: Renal impairment (RI) is associated with impaired prognosis in patients with coronary artery disease. Clinical and angiographic outcomes of patients undergoing percutaneous coronary intervention (PCI) with the use of drug-eluting stents (DES) in this patient population are not well estab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stefanini, Giulio G., Taniwaki, Masanori, Kalesan, Bindu, Räber, Lorenz, Stortecky, Stefan, Pilgrim, Thomas, Onuma, Yoshinobu, Silber, Sigmund, Serruys, Patrick W., Meier, Bernhard, Jüni, Peter, Windecker, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153613/ https://www.ncbi.nlm.nih.gov/pubmed/25184244 http://dx.doi.org/10.1371/journal.pone.0106450

Ejemplares similares

Additive Effect of Anemia and Renal Impairment on Long-Term Outcome after Percutaneous Coronary Intervention
por: Pilgrim, Thomas, et al.
Publicado: (2014)

Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction—TROFI II trial
por: Sabaté, Manel, et al.
Publicado: (2016)

Comparison of Zotarolimus- and Everolimus-Eluting Coronary Stents: Final 5-Year Report of the RESOLUTE All-Comers Trial
por: Iqbal, Javaid, et al.
Publicado: (2015)

Validation of the Valve Academic Research Consortium Bleeding Definition in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation
por: Stortecky, Stefan, et al.
Publicado: (2015)

‘Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI’: a post hoc analysis of the randomized GLOBAL LEADERS trial
por: Gamal, Amr S, et al.
Publicado: (2021)

Five‐Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus‐Eluting Stents Versus Durable Polymer Everolimus‐Eluting Stents
por: Iglesias, Juan F., et al.
Publicado: (2019)

Ultrathin Strut Biodegradable Polymer Sirolimus‐Eluting Stent Versus Durable‐Polymer Everolimus‐Eluting Stent for Percutaneous Coronary Revascularization: 2‐Year Results of the BIOSCIENCE Trial
por: Zbinden, Rainer, et al.
Publicado: (2016)

Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial
por: Gutiérrez-Chico, Juan Luis, et al.
Publicado: (2011)

Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug‐Eluting Stent Implantation: Per‐Protocol Analysis of the GLOBAL LEADERS Trial
por: Gragnano, Felice, et al.
Publicado: (2022)

Drug‐Eluting or Bare‐Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization
por: Piccolo, Raffaele, et al.
Publicado: (2021)

Post‐Procedural Troponin Elevation and Clinical Outcomes Following Transcatheter Aortic Valve Implantation
por: Koskinas, Konstantinos C., et al.
Publicado: (2016)

A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary artery lesions: The SPIRIT WOMEN study
por: Franzone, Anna, et al.
Publicado: (2017)

Clinical Outcome of High-Risk Patients with Severe Aortic Stenosis and Reduced Left Ventricular Ejection Fraction Undergoing Medical Treatment or TAVI
por: Pilgrim, Thomas, et al.
Publicado: (2011)

Stent Thrombosis and Restenosis with Contemporary Drug-Eluting Stents: Predictors and Current Evidence
por: Condello, Francesco, et al.
Publicado: (2023)

SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin
por: Dobner, Stephan, et al.
Publicado: (2022)

Protocol for a population-based study of rheumatic heart disease prevalence and cardiovascular outcomes among schoolchildren in Nepal
por: Pilgrim, Thomas, et al.
Publicado: (2012)

Mechanical complications in patients with ST-segment elevation myocardial infarction: A single centre experience
por: Lanz, Jonas, et al.
Publicado: (2019)

Self-reported non-adherence to P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: Application of the medication non-adherence academic research consortium classification
por: Ueki, Yasushi, et al.
Publicado: (2022)

Risk and Timing of Noncardiac Surgery After Transcatheter Aortic Valve Implantation
por: Okuno, Taishi, et al.
Publicado: (2022)

Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre‐Specified Analysis of the GLOBAL LEADERS Trial
por: Vranckx, Pascal, et al.
Publicado: (2021)

The 2010s in clinical drug-eluting stent and bioresorbable scaffold research: a Dutch perspective
por: Kawashima, H., et al.
Publicado: (2020)

Evaluation of Cumulative Meta-analysis of Rare Events as a Tool for Clinical Trials Safety Monitoring
por: Siontis, George C. M., et al.
Publicado: (2020)

Diagnostic performance of quantitative coronary artery disease assessment using computed tomography in patients with aortic stenosis undergoing transcatheter aortic-valve implantation
por: Malebranche, Daniel, et al.
Publicado: (2022)

Mortality, Stroke, and Hospitalization Associated With Deferred vs Expedited Aortic Valve Replacement in Patients Referred for Symptomatic Severe Aortic Stenosis During the COVID-19 Pandemic
por: Ryffel, Christoph, et al.
Publicado: (2020)

Staging cardiac damage associated with aortic stenosis in patients undergoing transcatheter aortic valve implantation
por: Okuno, Taishi, et al.
Publicado: (2021)

Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis
por: Stettler, Christoph, et al.
Publicado: (2008)

Comparative assessment of “plaque/media” change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study
por: Zeng, Yaping, et al.
Publicado: (2016)

Effect of Timing of Staged Percutaneous Coronary Intervention on Clinical Outcomes in Patients With Acute Coronary Syndromes
por: Otsuka, Tatsuhiko, et al.
Publicado: (2021)

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
por: Ouyang, Hang, et al.
Publicado: (2021)

Bioresorbable Drug-Eluting Magnesium-Alloy Scaffold for Treatment of Coronary Artery Disease
por: Campos, Carlos M., et al.
Publicado: (2013)

Conformability in everolimus-eluting bioresorbable scaffolds compared with metal platform coronary stents in long lesions
por: Fam, Jiang Ming, et al.
Publicado: (2017)

Age- and Gender-related Disparities in Primary Percutaneous Coronary Interventions for Acute ST-segment elevation Myocardial Infarction
por: Pilgrim, Thomas, et al.
Publicado: (2015)

Estrogen-Eluting Stents
por: Ryu, Sung Kee, et al.
Publicado: (2009)

Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary Intervention
por: Ueki, Yasushi, et al.
Publicado: (2019)

Two-year Clinical Outcomes of Patients with Long Segments Drug-Eluting Stents: Comparison of Sirolimus-Eluting Stent with Paclitaxel-Eluting Stent
por: Kim, Ung, et al.
Publicado: (2011)

Impact of Coronary Calcification on Clinical Outcomes After Implantation of Newer‐Generation Drug‐Eluting Stents
por: Hemetsberger, Rayyan, et al.
Publicado: (2021)

Early versus newer generation devices for transcatheter aortic valve implantation in routine clinical practice: a propensity score matched analysis
por: Pilgrim, Thomas, et al.
Publicado: (2018)

Patient-rated health status predicts prognosis following percutaneous coronary intervention with drug-eluting stenting
por: Pedersen, Susanne S., et al.
Publicado: (2010)

Everolimus-eluting stents versus sirolimus-eluting stents in patients with cardiac allograft vasculopathy
por: Hawranek, Michał, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9hbjih7drl57isu79vcgqhk605